Affiliation:
1. Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Abstract
Aim. To compare the effect of increased concentrations of aggregation inducers (five-fold addition) under standard conditions and under the conditions of vortex flow in vitro on platelet aggregation in patients with chronic heart failure (CHF).Materials and methods. The study included 28 patients. The activity of platelet aggregation in platelet-rich plasma (PRP) was evaluated according to light transmission curves (%) and the average size of aggregates (relative units (rel. units)). The aggregation inducer was added once at 10 seconds of the study (standard procedure) and five times at 10 seconds, 1, 2, 3, and 4 minutes of the study with a constant stirring rate of 800 rpm. The same parameters were evaluated under the conditions of vortex flow, which was created by changing the stirring rate of the PRP from 800 rpm to 0 rpm and again to 800 rpm by pressing the centrifugation button on the analyzer.Results. In the course of the study, the size of the aggregates increased in patients with CHF only under the conditions of vortex flow. When a collagen aggregation inducer was added both at the concentration of 2 mmol / l and 10 mmol / l, platelet aggregation parameters increased under the conditions of vortex flow. During the study of epinephrine-induced platelet aggregation in patients with CHF, an increase in the aggregation parameters was revealed, both at five-fold addition of the inducer and under the conditions of vortex flow compared with the standard method.Conclusion. The proposed methodological approaches to creating the conditions for vortex flow in vitro and to five-fold addition of epinephrine showed an increase in the size of the aggregates and the degree of platelet aggregation. Collagen-induced aggregation under the conditions of vortex flow revealed 7 (25%) patients with high residual platelet reactivity (HRPR), and epinephrine-induced aggregation detected 15 (54%) patients with HRPR.
Publisher
Siberian State Medical University
Reference21 articles.
1. Gus'kova E.V., Panchenko E.P., Komarov A.L., Dobrovol'skii A.B., Samko A.N. Ostatochnaya reaktivnost' trombotsitov k ADF i risk krovotechenii u bol'nykh stabil'noi IBS, poluchayushchikh dvoinuyu antirombotsitarnuyu terapiyu v svyazi s planovym chreskozhnym koronarnym vmeshatel'stvom. Rossiiskii kardiologicheskii zhurnal. 2015;3(119):35–42. DOI: 10.15829/1560-4071-2015-3-35-42.
2. Trubacheva O.A., Suslova T.E., Gusakova A.M., Kologrivova I.V., Shnaider O.L., Zavadovskii K.V. i dr. Vysokaya ostatochnaya agregatsionnaya aktivnost' trombotsitov u patsientov s ishemicheskoi bolezn'yu serdtsa: novyi metodicheskii podkhod k vyyavleniyu. Byulleten' sibirskoi meditsiny. 2021;20(2):113–119. DOI: 10.20538/1682-0363-2021-2-113-119.
3. Svarovskaya A.V., Teplyakov A.T. Insulinorezistentnost' pri sakharnom diabete. Kontrol' nad riskom kardiovaskulyarnykh oslozhnenii. Tomsk: NII kardiologii, Tomskii NIMTs, 2018:196.
4. Jastrzebska M., Marcinowska Z., Oledzki S. et al. Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease. Journal of Physiology and Pharmacology. 2018;69(4):595–605. DOI: 10.26402/jpp.2018.4.10.
5. Stone G.W., Witzenbichler B., Weisz G., Rinaldi M.J., Neumann F.-J., Metzger D.C. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–623. DOI: 10.1016/S0140-6736(13)61170-8.